Interesting fact: In a new study including Yale Cancer Center and Smilow Cancer Hospital researchers, the cancer immunotherapy drug pembrolizumab (Keytruda), increased survival for patients with advanced non-small cell lung cancer (NSCLC), a disease once considered an aggressive, and uniformly fatal cancer.
FACT SOURCE
0 Comments